A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia - Wikidata - awgldk - TriplyDB

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia

http://www.wikidata.org/entity/Q34770351

about

Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs Histamine H3 receptors and its antagonism as a novel mechanism for antipsychotic effect: a current preclinical & clinical perspective Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.Genetic Pharmacotherapy as an Early CNS Drug Development Strategy: Testing Glutaminase Inhibition for Schizophrenia Treatment in Adult Mice.Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia.Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors mGluR2/3 mechanisms in primate dorsolateral prefrontal cortex: evidence for both presynaptic and postsynaptic actions.Potential serotonergic agents for the treatment of schizophrenia.The impact of genetics on future drug discovery in schizophrenia.Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia.The dopamine D3 receptor, a quarter century later.Impaired Tuning of Neural Ensembles and the Pathophysiology of Schizophrenia: A Translational and Computational Neuroscience Perspective.Large-Scale Cognitive GWAS Meta-Analysis Reveals Tissue-Specific Neural Expression and Potential Nootropic Drug Targets.Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.Risperidone versus placebo for schizophrenia Investigating the role of mGluR2 versus mGluR3 in antipsychotic-like effects, sleep-wake architecture and network oscillatory activity using novel Han Wistar rats lacking mGluR2 expression

P2860

Q26744729-52E8B4F8-F205-4440-957C-75C12D9C5730 Q28073102-A0CBAA4F-6839-48A3-A2AC-EAAC98ABE752 Q30379983-23FFD97D-DE7E-40A8-A0CD-F7FB29D4150D Q33604654-A57F169D-AB79-42D1-97CE-08F1B6115B38 Q36063631-411F1201-10AB-4A66-927B-D4BBA6DCE807 Q36441844-99A8370F-E5E0-4C35-8C5E-AE77F27C8175 Q36735985-A28BA1BD-80F7-4487-8384-00D3D383E7D2 Q37183072-441B6D17-DAD8-47D9-861C-1BC323F13764 Q37632867-91DFD86B-AAB9-4A2E-AF0D-DAD48E2F61C1 Q38635792-A8113FE4-299E-4561-8A12-62D3434945B1 Q38682213-580B3FA6-F908-4ED5-AE69-F9FF9CF52140 Q38699013-4543C513-CD39-4D28-9AC2-6B558EFA5CB7 Q38718345-BC331A49-E9CA-4714-8EC0-74BDDC4CE990 Q38863895-D09CA87C-8474-452F-9AE9-4B22A5B69005 Q38947750-5059F85F-D210-4130-81D4-EBA10729FD1C Q39257224-C26E4D7B-50B1-4912-A7A1-7103DF841AA2 Q47569499-89E95EAB-1588-4B28-B260-CB6D63E38A27 Q54978405-226591E9-298A-445D-89B3-5559B82D0940 Q55894951-369FD22E-9701-4EBF-93CF-DF0D400F3782 Q58737944-12708FF2-0F6B-4247-840A-67B10D68274C

P2860

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia

http://www.wikidata.org/entity/Q34770351

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A Double-Blind, Placebo-Contro ...... in patients with schizophrenia

@ast

A Double-Blind, Placebo-Contro ...... in patients with schizophrenia

@en

A Double-Blind, Placebo-Contro ...... in patients with schizophrenia

@nl

type

label

A Double-Blind, Placebo-Contro ...... in patients with schizophrenia

@ast

A Double-Blind, Placebo-Contro ...... in patients with schizophrenia

@en

A Double-Blind, Placebo-Contro ...... in patients with schizophrenia

@nl

prefLabel

A Double-Blind, Placebo-Contro ...... in patients with schizophrenia

@ast

A Double-Blind, Placebo-Contro ...... in patients with schizophrenia

@en

A Double-Blind, Placebo-Contro ...... in patients with schizophrenia

@nl

P1433

Q34770351-7BCF5829-15DF-4E9F-9B1C-F1A3664462B0

P1476

Q34770351-5A8A4C3F-59A4-4AB1-9769-1B1404E2B2BD

P2093

Q34770351-389315C1-8BF3-44AA-8C18-1611B415FE9C

Q34770351-4CC657A5-A176-4CA4-98CD-78013156A733

Q34770351-4E581CAA-284B-495D-9834-FABC224E9D73

Q34770351-502F4280-D13E-48DF-A30E-AEE725924CF5

Q34770351-601456AB-9D90-47D8-ABBB-7A35C448A8F9

Q34770351-6980CD2A-8CE7-493B-A3B0-263911978482

Q34770351-99ED1726-731B-48D2-8E2C-2ACAE0A6B6F1

Q34770351-CD6EE08C-BFE2-4CA1-BE05-90FD3C5B5C98

Q34770351-F962FE26-1066-4926-8724-B6F1A15E5418

Q34770351-FA2538A8-B323-41EC-A8E4-63819973CE10

P2860

Q34770351-0209301B-19C8-41EC-B9A3-0B057FD3CA34

Q34770351-02CE8ABD-BFE8-4555-87D1-B2F687CD5D4B

Q34770351-044B2FD1-2D98-424D-862D-407591D1B081

Q34770351-14563B2A-B72D-49B9-A987-91149376799B

Q34770351-1CECC83C-4943-43EF-A48D-BD90B2D0FAAF

Q34770351-3AA2A68E-8B8B-4680-AED2-02C7A3E95D48

Q34770351-41463572-C33F-42C6-9BAE-B7E7854AA1E3

Q34770351-48824370-3E4E-4B7D-8BF2-681C8F3A30F6

Q34770351-4B061840-77A4-44C5-888F-C9F18AB6029B

Q34770351-4C222A17-90D8-4705-8F4A-C716B34D9BDB

P2888

Q34770351-696D8EB7-1236-4A71-8DBE-1864A5C6F539

P304

Q34770351-B02696B1-0C86-43F1-83DB-375947BF4F52

P31

Q34770351-E133ED9E-83BF-467A-BCE7-B134A9BC3A71

P356

Q34770351-4865298F-D60C-465B-8AE5-83CF35680E56

P478

Q34770351-CCD03CFA-B68B-43C1-8B0C-F3373BACEF37

P50

Q34770351-85B12ED5-1879-4D15-A38F-BAC58F516B32

P577

Q34770351-88B0F56B-D310-4624-A469-1B23FE3F1C64

P5875

Q34770351-EEB7FCB6-BD68-4025-9E8F-ACD4F6D939F3

P6179

Q34770351-7E233828-F88A-46FD-8744-284703F63D43

P698

Q34770351-CB7CDCEC-7CB4-4572-B647-D6A17D90CBD5

P921

Q34770351-7543306B-CC5A-46FB-AE37-D9BCAF846609

Q34770351-E38DC039-CA42-4681-9EC8-D5A8E6C6EA99

P932

Q34770351-EA9C3890-8C4D-4616-837F-490F2AC274EE

P356

S12888-014-0351-3

P1433

P1476

A Double-Blind, Placebo-Contro ...... in patients with schizophrenia

@en

P2093

AnnCatherine M Downing

http://www.w3.org/2001/XMLSchema#string

Brian A Millen

http://www.w3.org/2001/XMLSchema#string

Bruce J Kinon

http://www.w3.org/2001/XMLSchema#string

Fangyi Zhao

http://www.w3.org/2001/XMLSchema#string

Juan Carlos Gomez

http://www.w3.org/2001/XMLSchema#string

Laura Nisenbaum

http://www.w3.org/2001/XMLSchema#string

Lin Liu

http://www.w3.org/2001/XMLSchema#string

Lu Zhang

http://www.w3.org/2001/XMLSchema#string

Ronald Brenner

http://www.w3.org/2001/XMLSchema#string

Tami Jo Rayle

http://www.w3.org/2001/XMLSchema#string

P2860

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

A rating scale for drug-induced akathisia

The positive and negative syndrome scale (PANSS) for schizophrenia

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.

Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Translating glutamate: from pathophysiology to treatment.

Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.

P2888

s12888-014-0351-3

P304

351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12888-014-0351-3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Margarita Morozova

P577

2014-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269415114

http://www.w3.org/2001/XMLSchema#string

P6179

1041660391

http://www.w3.org/2001/XMLSchema#string

P698

25539791

http://www.w3.org/2001/XMLSchema#string

P921

P932

4276262

http://www.w3.org/2001/XMLSchema#string